Firms raise price targets for Apple, Merck, and Nvidia citing product demand, pipeline strength, and AI-driven growth ahead of earnings.
Analysts upgraded Apple, Merck, and Nvidia this week, citing robust product strategies, improved drug pipelines, and strong AI-driven demand. Nvidia’s price target was raised ahead of earnings on expectations of sustained sales growth from the AI cycle.
Prior upgrades for Apple highlighted execution strength, while Merck’s pipeline advancements offset valuation concerns raised by RBC. Okta also saw upgrades due to rising demand, contrasting with Baidu’s downgrade over weak advertising revenue and high AI investment costs.
The calls reflect divergent sector outlooks, with tech and healthcare favored for near-term upside.